InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for…
<!-- Name:DistributionId Value:8802103 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
C5a
InflaRx Announces Amendment of Co-Development Agreement and Additional Equity…
InflaRx will provide access to certain clinical, manufacturing and regulatory documentation for vilobelimab to facilitate STS’s regulatory filings in ChinaSTS plans to request regulatory…
Targeting C5a Doesn’t Help Ventilated COVID Patients … or Does It?
An anti-C5a antibody failed to show a statistically significant mortality reduction in…
InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker…
JENA, Germany, March 08, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the…